Trial · NCT03385239
Adverse events290
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 290
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Pooled Placebo | 3 | 24 | |
| other | Nasopharyngitis | Infections and infestations | Cohort A: ISIS 678354: 10 mg Q4W | 3 | 22 | |
| other | Nasopharyngitis | Infections and infestations | Cohort C: ISIS 678354: 15 mg Q2W | 4 | 23 | |
| other | Nasopharyngitis | Infections and infestations | Cohort D: ISIS 678354: 10 mg QW | 5 | 23 | |
| other | Nasopharyngitis | Infections and infestations | Cohort B: ISIS 678354: 50 mg Q4W | 4 | 22 | |
| other | Upper respiratory tract infection | Infections and infestations | Pooled Placebo | 3 | 24 | |
| other | Upper respiratory tract infection | Infections and infestations | Cohort A: ISIS 678354: 10 mg Q4W | 2 | 22 | |
| other | Upper respiratory tract infection | Infections and infestations | Cohort C: ISIS 678354: 15 mg Q2W | 3 | 23 | |
| other | Upper respiratory tract infection | Infections and infestations | Cohort D: ISIS 678354: 10 mg QW | 4 | 23 | |
| other | Upper respiratory tract infection | Infections and infestations | Cohort B: ISIS 678354: 50 mg Q4W | 3 | 22 | |
| other | Urinary tract infection | Infections and infestations | Pooled Placebo | 1 | 24 | |
| other | Urinary tract infection | Infections and infestations | Cohort A: ISIS 678354: 10 mg Q4W | 2 | 22 | |
| other | Urinary tract infection | Infections and infestations | Cohort C: ISIS 678354: 15 mg Q2W | 2 | 23 | |
| other | Urinary tract infection | Infections and infestations | Cohort D: ISIS 678354: 10 mg QW | 1 | 23 | |
| other | Urinary tract infection | Infections and infestations | Cohort B: ISIS 678354: 50 mg Q4W | 4 | 22 | |
| other | Bronchitis | Infections and infestations | Pooled Placebo | 2 | 24 | |
| other | Bronchitis | Infections and infestations | Cohort A: ISIS 678354: 10 mg Q4W | 1 | 22 | |
| other | Bronchitis | Infections and infestations | Cohort C: ISIS 678354: 15 mg Q2W | 2 | 23 | |
| other | Bronchitis | Infections and infestations | Cohort D: ISIS 678354: 10 mg QW | 2 | 23 | |
| other | Bronchitis | Infections and infestations | Cohort B: ISIS 678354: 50 mg Q4W | 2 | 22 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03385239/events